NCT01344798View on ClinicalTrials.gov

Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Limb Girdle Muscular Dystrophy Type 2CGamma-sarcoglycanopathy
Interventions
BIOLOGICAL

AAV1-gamma-sarcoglycan vector injection

single intramuscular injection into carpi radialis muscle under open procedure

Trial Locations (1)

75013

Hôpital Pitié-Salpêtrière, Paris

Sponsors

Lead Sponsor

Genethon
All Listed Sponsors
lead

Genethon

OTHER

NCT01344798 - Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C | Biotech Hunter | Biotech Hunter